JP4695262B2 - 置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤 - Google Patents

置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤 Download PDF

Info

Publication number
JP4695262B2
JP4695262B2 JP2000583875A JP2000583875A JP4695262B2 JP 4695262 B2 JP4695262 B2 JP 4695262B2 JP 2000583875 A JP2000583875 A JP 2000583875A JP 2000583875 A JP2000583875 A JP 2000583875A JP 4695262 B2 JP4695262 B2 JP 4695262B2
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
formula
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000583875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002530385A (ja
JP2002530385A5 (enExample
Inventor
ウルズラ・シンドラー
カール・シェーナフィンガー
ハルトムート・シュトローベル
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2002530385A publication Critical patent/JP2002530385A/ja
Publication of JP2002530385A5 publication Critical patent/JP2002530385A5/ja
Application granted granted Critical
Publication of JP4695262B2 publication Critical patent/JP4695262B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000583875A 1998-11-19 1999-11-03 置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤 Expired - Fee Related JP4695262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19853278A DE19853278A1 (de) 1998-11-19 1998-11-19 Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19853278.4 1998-11-19
PCT/EP1999/008382 WO2000031047A1 (de) 1998-11-19 1999-11-03 Substituierte 4-amino-2-aryl-cyclopenta[d]pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate

Publications (3)

Publication Number Publication Date
JP2002530385A JP2002530385A (ja) 2002-09-17
JP2002530385A5 JP2002530385A5 (enExample) 2006-12-14
JP4695262B2 true JP4695262B2 (ja) 2011-06-08

Family

ID=7888276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000583875A Expired - Fee Related JP4695262B2 (ja) 1998-11-19 1999-11-03 置換４−アミノ−２−アリールシクロペンタ［ｄ］ピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤

Country Status (10)

Country Link
US (2) US6627628B1 (enExample)
EP (1) EP1131302B1 (enExample)
JP (1) JP4695262B2 (enExample)
AT (1) ATE316964T1 (enExample)
AU (1) AU1159400A (enExample)
CA (1) CA2351488C (enExample)
DE (2) DE19853278A1 (enExample)
ES (1) ES2257103T3 (enExample)
PT (1) PT1131302E (enExample)
WO (1) WO2000031047A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853278A1 (de) * 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7031977B2 (en) * 2002-02-28 2006-04-18 Plumtree Software, Inc. Efficiently storing indented threads in a threaded discussion application
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
EP1663994B1 (en) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
PT1689715E (pt) 2003-12-03 2011-05-16 Ym Biosciences Australia Pty Inibidores da tubulina
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
MX2009014013A (es) * 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
EP2242757B1 (en) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
US8835434B2 (en) * 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CA3181583A1 (en) * 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN113880859B (zh) * 2021-11-16 2022-06-21 江西科技师范大学 2-芳基-4-芳甲胺基嘧啶类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3346452A (en) 1963-08-19 1967-10-10 Ciba Geigy Corp 5, 6-lower alkylene-pyrimidines
DE4029654A1 (de) * 1990-09-19 1992-04-02 Hoechst Ag 2-phenyl-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
JPH07228573A (ja) * 1994-02-16 1995-08-29 Dainippon Pharmaceut Co Ltd ２−フェニルシクロアルカノピリミジン誘導体
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
ATE431347T1 (de) 1996-10-14 2009-05-15 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19853278A1 (de) * 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
US6627628B1 (en) 2003-09-30
WO2000031047A1 (de) 2000-06-02
US20040048850A1 (en) 2004-03-11
AU1159400A (en) 2000-06-13
ATE316964T1 (de) 2006-02-15
US7138398B2 (en) 2006-11-21
PT1131302E (pt) 2006-05-31
JP2002530385A (ja) 2002-09-17
CA2351488C (en) 2009-12-29
DE19853278A1 (de) 2000-05-25
CA2351488A1 (en) 2000-06-02
EP1131302A1 (de) 2001-09-12
ES2257103T3 (es) 2006-07-16
DE59913103D1 (de) 2006-04-13
EP1131302B1 (de) 2006-02-01

Similar Documents

Publication Publication Date Title
JP4594526B2 (ja) 置換４−アミノ−２−アリールピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤
US6627628B1 (en) Substituted 4-amino-2-aryl-cyclopenta[d]pyrimidines, their production and use and pharmaceutical preparations containing same
US6613772B1 (en) Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
JP4700194B2 (ja) 置換４−アミノ−２−アリールテトラヒドロキナゾリン、その製造、その使用およびそれを含む医薬組成物
JP4422335B2 (ja) グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸ｎ−アリールアミド
WO2003074525A1 (fr) Compose heterocyclique azote
MXPA01001411A (en) Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100323

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110225

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees